nach oben

Psychiatric Quarterly

Erschienen in:

01.06.2008 | Original Paper

Comorbid Anxiety in Bipolar Disorder Alters Treatment and Prognosis

verfasst von: Rif S. El-Mallakh, Michael Hollifield

Erschienen in: Psychiatric Quarterly | Ausgabe 2/2008

Einloggen, um Zugang zu erhalten

Abstract

Mood disorders in general, and bipolar disorder in particular, are unique among the psychiatric conditions in that they are associated with extraordinarily high rates of comorbidity with a multitude of psychiatric and medical conditions. Among all the potential cormobidities, co-occurring anxiety disorders stand out due to their very high prevalence. Outcome in bipolar illness is worse in the presence of a comorbid anxiety disorder. The coexistence of an anxiety disorder presents a particularly difficult challenge in the treatment of bipolar illness since antidepressants, the mainstay of pharmacologic treatments for anxiety, may adversely alter the course of manic-depression. Identification of anxiety disorders in bipolar patients is important. The treatment plan needs to balance the potential benefit and harm of antidepressant administration.

Maremmani I, Perugi G, Pacini M, et al.: Toward a unitary perspective on the bipolar spectrum and substance abuse: opiate addiction as a paradigm. Journal of Affective Disorders 93(1–3):1–12, 2006PubMedCrossRef

McElroy SL, Kotwal R, Keck PE Jr, et al.: Comorbidity of bipolar and eating disorders: distinct or related disorders with shared dysregulations? Journal of Affective Disorders 86(2–3):107–127, 2005PubMedCrossRef

American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders-Text Revision, ed 4, revised. Arlington, VA, American Psychiatric Association, 2000

Merikangas KR, Akiskal HS, Angst J, et al.: Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Archives of General Psychiatry 64(5):543–552, 2007PubMedCrossRef

Angst J, Gamma A, Benazzi F, et al.: Toward a re-definition of subthreshold bipolarity: epidemiology and proposed criteria for bipolar-II, minor bipolar disorders and hypomania. Journal of Affective Disorders 73(1–2):133–146, 2003PubMedCrossRef

Tohen M, Strakowski SM, Zarate C Jr, et al.: The McLean–Harvard first-episode project: 6-month symptomatic and functional outcome in affective and nonaffective psychosis. Biological Psychiatry 48:467–476, 2000PubMedCrossRef

Tohen M, Zarate CA Jr, Hennen J, et al.: The McLean–Harvard first-episode mania study: Prediction of recovery and first recurrence. American Journal of Psychiatry 160:2099–2107, 2003PubMedCrossRef

Murray CJL, Lopez AD (eds): The global burden of disease and injury series, volume 1: a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Cambridge, MA, Harvard University Press, 1996

Martinez-Aran A, Vieta E, Torrent C, et al.: Functional outcome in bipolar disorder: the role of clinical and cognitive factors. Bipolar Disorders 9(1–2):103–113, 2007PubMedCrossRef

10.

Conus P, Cotton S, Abdel-Baki A, et al.: Symptomatic and functional outcome 12 months after a first episode of psychotic mania: barriers to recovery in a catchment area sample. Bipolar Disorders 8:221–231, 2006PubMedCrossRef

11.

DelBello MP, Hanseman D, Adler CM, et al.: Twelve-month outcome of adolescents with bipolar disorder following first hospitalization for a manic or mixed episode. American Journal of Psychiatry 164:582–590, 2007PubMedCrossRef

12.

Sareen J, Cox BJ, Afifi TO, et al.: Anxiety disorders and risk for suicidal ideation and suicide attempts: a population-based longitudinal study of adults. Archives of General Psychiatry 62:1249–1257, 2005PubMedCrossRef

13.

Rodriguez BF, Bruce SE, Pagano ME, et al.: Relationships among psychosocial functioning, diagnostic comorbidity, and the recurrence of generalized anxiety disorder, panic disorder, and major depression. Journal of Anxiety Disorders 19:752–766, 2005PubMedCrossRef

14.

Weissman MM, Klerman GL, Markowitz JS, et al.: Suicidal ideation and suicide attempts in panic disorder and attacks. New England Journal of Medicine 321(18):1209–1214, 1989PubMed

15.

Klerman GL, Weissman MM, Ouellette R, et al.: Panic attacks in the community. Social morbidity and health care utilization. JAMA 265(6):742–746, 1991PubMedCrossRef

16.

Kessler RC, McGonagle KA, Zhao S, et al.: Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Archives of General Psychiatry 51:8–19, 1994PubMed

17.

Kessler RC, Rubinow DR, Holmes C et al.: The epidemiology of DSM-III-R bipolar I disorder in a general population survey. Psychological Medicine 27:1079–1089, 1997PubMedCrossRef

18.

Feske U, Frank E, Mallinger AG, et al.: Anxiety as a correlate of response to the acute treatment of bipolar I disorder. American Journal of Psychiatry 157:956–962, 2000PubMedCrossRef

19.

Boylan KR, Bieling PJ, Marriott M et al.: Impact of comorbid anxiety disorders on outcome in a cohort of patients with bipolar disorder. Journal of Clinical Psychiatry 65:1106–1113, 2004PubMed

20.

Harpold TL, Wozniak J, Kwon A, et al.: Examining the association between pediatric bipolar disorder and anxiety disorders in psychiatrically referred children and adolescents. Journal of Affective Disorders 88:19–26, 2005PubMedCrossRef

21.

Dickstein DP, Rich BA, Binstock AB, et al.: Comorbid anxiety in phenotypes of pediatric bipolar disorder. Journal of Child and Adolescent Psychopharmacology 15:534–548, 2005PubMedCrossRef

22.

Chen YW, Dilsaver SC: Comorbidity of panic disorder in bipolar illness: evidence from the epidemiologic catchment area survey. American Journal of Psychiatry 152:280–282, 1995PubMed

23.

Doughty CJ, Wells JE, Joyce PR, et al.: Bipolar-panic disorder comorbidity within bipolar disorder families: a study of siblings. Bipolar Disorders 6:245–252, 2004PubMedCrossRef

24.

MacKinnon DF, Xu J, McMahon FJ, et al.: Bipolar disorder and panic disorder in families: an analysis of chromosome 18 data. American Journal of Psychiatry 155:829–831, 1998PubMed

25.

Chen YW, Dilsaver SC: Comorbidity for obsessive-compulsive disorder in bipolar and unipolar disorders. Psychiatry Research 59:57–64, 1995PubMedCrossRef

26.

Fogarty F, Russel JM, Newman SC, et al.: Epidemiology of psychiatric disorders in Edmonton: mania. Acta Psychiatrica Scandinavica 376(Suppl):16–23, 1994CrossRef

27.

Perugi G, Akiskal HS, Lattanzi L, et al.: The high prevalence of “soft” bipolar (II) features in atypical depression. Comprehensive Psychiatry 39:63–71, 1998PubMedCrossRef

28.

Strakowski SM, Sax KW, McElroy SL, et al.: Course of psychiatric and substance abuse syndromes co-occurring with bipolar disorder after a first psychiatric hospitalization. Journal of Clinical Psychiatry 59:465–471, 1998PubMed

29.

Pini S, Dell’Osso L, Mastrocinque C, et al.: Axis I comorbidity in bipolar disorder with psychotic features. British Journal of Psychiatry 175:467–471, 1999PubMed

30.

Vieta E, Colom F, Corbella B, et al.: Clinical correlates of psychiatric comorbidity in bipolar I patients. Bipolar Disorders 3:253–258, 2001PubMedCrossRef

31.

Yerevanian BI, Koek RJ, Ramdev S: Anxiety disorders comorbidity in mood disorder subgroups: data from a mood disorders clinic. Journal of Affective Disorders 67:167–173, 2001PubMedCrossRef

32.

Altindag A, Yanik M, Nebioglu M: The comorbidity of anxiety disorders in bipolar I patients: prevalence and clinical correlates. Israel Journal of Psychiatry and Related Sciences 43:10–15, 2006PubMed

33.

Coryell W, Endicott J, Andreasen N, et al.: Bipolar I, bipolar II, and nonbipolar major depression among the relatives of affectively ill probands. American Journal of Psychiatry 142:817–821, 1985PubMed

34.

Swartz CM, Shen WW: Is episodic obsessive compulsive disorder bipolar? A report of four cases. Journal of Affective Disorders 56:61–66, 1999PubMedCrossRef

35.

Masi G, Perugi G, Toni C, et al.: Obsessive-compulsive bipolar comorbidity: focus on children and adolescents. Journal of Affective Disorders 78:175–183, 2004PubMedCrossRef

36.

Brown GR, McBride L, Bauer MS, et al.: Impact of childhood abuse on the course of bipolar disorder: a replication study in U.S. veterans. Journal of Affective Disorders 89:57–67, 2005CrossRef

37.

Goldberg JF, Garno JL: Development of posttraumatic stress disorder in adult bipolar patients with histories of severe childhood abuse. Journal of Psychiatric Research 39:595–601, 2005PubMedCrossRef

38.

Kennedy BL, Dhaliwal N, Pedley L, et al.: Post-traumatic stress disorder in subjects with schizophrenia and bipolar disorder. Journal of the Kentucky Medical Association 100:395–399, 2002PubMed

39.

Pollack MH, Simon NM, Fagiolini A, et al.: Persistent posttraumatic stress disorder following September 11 in patients with bipolar disorder. Journal of Clinical Psychiatry 67:394–357, 2006PubMed

40.

Otto MW, Perlman CA, Wernicke R, et al.: Posttraumatic stress disorder in patients with bipolar disorder: a review of prevalence, correlates, and treatment strategies. Bipolar Disorders 6:470–479, 2004PubMedCrossRef

41.

Baldassano CF, Marangell LB, Gyulai L, et al.: Gender differences in bipolar disorder: retrospective data from the first 500 STEP-BD participants. Bipolar Disorders 7:465–470, 2005PubMedCrossRef

42.

Henin A, Biederman J, Mick E, et al.: Psychopathology in the offspring of parents with bipolar disorder: a controlled study. Biological Psychiatry 58:554–561, 2005PubMedCrossRef

43.

Grant BF, Hasin DS, Blanco C et al.: The epidemiology of social anxiety disorder in the United States: results from the National Epidemiologic survey on Alcohol and Related Conditions. Journal of Clinical Psychiatry 66:1351–1361, 2005PubMed

44.

Gaudiano BA, Miller IW: Anxiety disorder comorbidity in bipolar I disorder: relationship to depression severity and treatment outcome. Depression and Anxiety 21:71–77, 2005PubMedCrossRef

45.

Keller MB: Prevalence and impact of comorbid anxiety and bipolar disorder. Journal of Clinical Psychiatry 67(Suppl 1):5–7, 2006PubMed

46.

Allen MH, Chessick CA, Miklowitz DJ, et al.: Contributors to suicidal ideation among bipolar patients with and without a history of suicide attempts. Suicide and Life Threatening Behavior 35:671–680, 2005PubMedCrossRef

47.

Young LT, Cooke RG, Robb JC, et al.: Anxious and non-anxious bipolar disorder. Journal of Affective Disorders 29:49–52, 1993PubMedCrossRef

48.

Perlis RH, Miyahara S, Marangell LB, et al.: Long-Term implications of early onset in bipolar disorder: data from the first 1000 participants in the systematic treatment enhancement program for bipolar disorder (STEP-BD). Biological Psychiatry 55(9):875–881, 2004PubMedCrossRef

49.

Otto MW, Simon NM, Wisniewski SR et al.: Prospective 12-month course of bipolar disorder in out-patients with and without comorbid anxiety disorders. British Journal of Psychiatry 189:20–25, 2006PubMedCrossRef

50.

Simon NM, Zalta AK, Otto MW, et al.: The association of comorbid anxiety disorders with suicide attempts and suicidal ideation in outpatients with bipolar diosorder. Journal Psychiatric Research 41:255–264, 2007CrossRef

51.

Simon NM, Otto MW, Wisniewski SR, et al.: Anxiety disorder comorbidity in bipolar disorder patients: data from the first 500 participants in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). American Journal of Psychiatry 161:2222–2229, 2004PubMedCrossRef

52.

Matza LS, Rajagopalan KS, Thompson CL, et al.: Misdiagnosed patients with bipolar disorder: comorbidities, treatment patterns, and direct treatment costs. Journal of Clinical Psychiatry 66:1432–1440, 2005PubMed

53.

Hollifield M, Mackey A, Davidson J: Integrating therapies for anxiety disorders. Psychiatric Annals 36:329–338, 2006

54.

van der Kolk BA, Spinazzola J, Blaustein ME, et al.: A randomized clinical trial of eye movement desensitization and reprocessing (EMDR), fluoxetine, and pill placebo in the treatment of posttraumatic stress disorder: treatment effects and long-term maintenance. Journal of Clinical Psychiatry 68:37–46, 2007PubMedCrossRef

55.

Asnis GM, Kohn SR, Henderson M, et al.: SSRIs versus non-SSRIs in post-traumatic stress disorder: an update with recommendations. Drugs 64:383–404, 2004PubMedCrossRef

56.

Marshall RD, Beebe KL, Oldham M, et al.: Efficacy and safety of paroxetine treatment for chronic PTSD: a fixed-dose, placebo-controlled study. American Journal of Psychiatry 158(12):1982–1988, 2001PubMedCrossRef

57.

Tucker P, Zaninelli R, Yehuda R, et al.: Paroxetine in the treatment of chronic posttraumatic stress disorder: results of a placebo-controlled, flexible-dosage trial. Journal of Clinical Psychiatry 62(11):860–868, 2001PubMed

58.

Pollack MH, Lepola U, Kpenen H, et al.: A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder. Depression and Anxiety 24(1):1–14, 2007PubMedCrossRef

59.

Pollack MH, Mangano R, Entsuah R, et al.: A randomized controlled trial of venlafaxine ER and paroxetine in the treatment of outpatients with panic disorder. Psychopharmacology (Berlin) 2007 (Epub ahead of print)

60.

Shuurmans J, Comijs H, Emmelkamp PM, et al.: A randomized, controlled trial of the effectiveness of cognitive-behavioral therapy and sertraline versus a waitlist control group for anxiety disorders in older adults. American Journal of Geriatric Psychiatry 14:255–263, 2006CrossRef

61.

Kamijima K, Kuboki T, Kumano H, et al.: A placebo-controlled, randomized withdrawal study of sertraline for panic disorder in Japan. International Clinical Psychopharmacology 20(5):265–273, 2005PubMedCrossRef

62.

Stahl SM, Gergel I, Li D: Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trial. Journal of Clinical Psychiatry 64:1322–1327, 2003PubMedCrossRef

63.

Londborg PD, Wolkow R, Smith WT et al.: Sertraline in the treatment of panic disorder. A multi-site, double-blind, placebo-controlled, fixed-dose investigation. British Journal of Psychiatry 173:54–60, 1998PubMed

64.

Oehrberg S, Christiansen PE, Behnke K, et al.: Paroxetine in the treatment of panic disorder: a randomized, double-blind, placebo-controlled study. British Journal of Psychiatry 167:374–379, 1995PubMedCrossRef

65.

Brawman-Mintzer O, Knapp RG, et al.: Sertraline treatment for generalized anxiety disorder: a randomized, double-blind, placebo-controlled study. Journal of Clinical Psychiatry 67(6):874–881, 2006PubMed

66.

Goodman WK, Bose A, Wang Q: Treatment of generalized anxiety disorder with escitalopram: pooled results from double-blind, placebo-controlled trials. Journal of Affective Disorders 87(2–3):161–167, 2005PubMedCrossRef

67.

Davidson JR, Bose A, Korotzer A, et al.: Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study. Depression and Anxiety 19:234–240, 2004PubMedCrossRef

68.

Hedges DW, Brown BL, Shwalb DA, et al.: The efficacy of selective serotonin reuptake inhibitors in adult social anxiety disorder: a meta-analysis of double-blind, placebo-controlled trials. Journal of Psychopharmacology 21(1):102–111, 2007PubMedCrossRef

69.

Stein DJ, Andersen EW, Tonnoir B, et al.: Escitalopram in obsessive-compulsive disorder: a randomized, placebo-controlled, paroxetine-referenced, fixed-dose, 24-week study. Current Medical Research and Opinion 23:701–711, 2007PubMedCrossRef

70.

Pallanti S, Quercioli L, Koran LM: Citalopram intravenous infusion in resistant obsessive-compulsive disorder: an open trial. Journal of Clinical Psychiatry 63:796–801, 2002PubMed

71.

Montgomery SA, Kasper S, Stein DJ, et al.: Citalopram 20 mg, 40 mg, and 60 mg are all effective and well tolerated compared with placebo in obsessive-compulsive disorder. International Clinical Psychopharmacology 16:75–86, 2001PubMedCrossRef

72.

Becker ME, Hertzberg MA, Moore SD, et al.: A placebo-controlled trial of bupropion SR in the treatment of chronic posttraumatic stress disorder. Journal of Clinical Psychopharmacology 27:193–197, 2007PubMedCrossRef

73.

El-Mallakh RS, Karippot A: Use of antidepressants to treat depression in bipolar disorder. Psychiatric Services 53:580–584, 2002PubMedCrossRef

74.

Ghaemi SN, Hsu DJ, Soldani F, et al.: Antidepressants in bipolar disorder: the case for caution. Bipolar Disorders 5(6):421–433, 2003PubMedCrossRef

75.

El-Mallakh RS, Karippot A: Chronic depression in bipolar disorder. American Journal of Psychiatry 163:1337–1341 (quiz on 1478), 2006

76.

El-Mallakh RS, Karippot A: Antidepressant-associated chronic irritable dysphoria (ACID) in bipolar disorder. Journal of Affect Disorders 84:267–272, 2005CrossRef

77.

Kukopulos A, Caliari B, Tundo A, et al.: Rapid Cyclers, temperament, and antidepressants. Comprehensive Psychiatry 24:249–258, 1983PubMedCrossRef

78.

Altshuler LL, Post RM, Leverich GS, et al.: Antidepressant-induced mania and cycle acceleration: a controversy revisited. American Journal of Psychiatry 152:1130–1138, 1995PubMed

79.

Simon NM, Otto MW, Weiss RD, et al.: Pharmacotherapy for bipolar disorder and comorbid conditions: baseline data from STEP-BD. Journal of Clinical Psychopharmacollogy 24:512–520, 2004CrossRef

80.

Lembke A, Miklowitz DJ, Otto MW, et al.: Psychosocial service utilization by patients with bipolar disorders: data from the first 500 participants in the Systematic Treatment Enhancement Program. Journal of Psychiatric Practice 10:81–87, 2004PubMedCrossRef

81.

Pande AC, Davidson JR, Jefferson JW, et al.: Treatment of social phobia with gabapentin: a placebo-controlled study. Journal of Clinical Psychopharmacology 19(4):341–348, 1999PubMedCrossRef

82.

Pande AC, Pollack MH, Crockatt J et al.: Placebo-controlled study of gabapentin treatment of panic disorder. Journal of Clinical Psychopharmacology 20(4):467–471, 2000PubMedCrossRef

83.

Sepede G, De Berardis D, Gambi F, et al.: Olanzapine augmentation in treatment-resistant panic disorder: a 12-week, fixed-dose, open-label trial. Journal of Clinical Psychopharmacology 26:45–49, 2006PubMedCrossRef

84.

Hollifield M, Thompson PM, Ruiz JE, et al.: Potential effectiveness and safety of olanzapine in refractory panic disorder. Depression and Anxiety 21:33–40, 2005PubMedCrossRef

85.

Hirshfeld RM, Weisler RH, Raines SR, et al.: Quetiapine in the treatment of anxiety in patients with bipolar I or II depression: a secondary analysis from a randomized, double-blind, placebo-controlled study. Journal of Clinical Psychiatry 67:355–363, 2006

86.

Bystritsky A, Ackerman DL, Rosen RM, et al.: Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial. Journal of Clinical Psychiatry 65:565–568, 2004PubMed

87.

Oruc L, Cavuljuga S: Olanzapine in treatment of patients with bipolar I disorder and panic comorbidity: a case study. Bosnian Journal of Basic Medical Science 3:67–69, 2003

88.

Hamner MB, Robert S, Frueh C: Treatment-resistant posttraumatic stress disorder: strategies for intervention. CNS Spectrums 9:740–752, 2004PubMed

89.

Keck PE Jr, McElroy SL, Friedman LM: Valproate and carbamazepine in the treatment of panic and posttraumatic stress disorders, withdrawal states, and behavioral dyscontrol syndromes. Journal of Clinical Psychopharmacology 12(1 Suppl):36S–41S, 1992PubMed

90.

Munjack DJ, Croker B, Cabe D et al.: Alprazolam, propranolol, and placebo in the treatment of panic disorder and agoraphobia with panic attacks. Journal of Clinical Psychopharmacology 9:22–27, 1989PubMedCrossRef

91.

Swinson RP, Pecknold JC, Kuch K: Psychopharmacological treatment of panic disorder and related states: a placebo controlled study of alprazolam. Progress in Neuropsychopharmacology and Biological Psychiatry 11:105–113, 1987CrossRef

92.

Chouinard G: The use of benzodiazepines in the treatment of manic-depressive illness. Journal of Clinical Psychiatry 49(Suppl):15–20, 1988PubMed

93.

Valença AM, Nardi AE, Nascimento I, Mezzasalma MA, Lopes FL, Zin W: Double-blind clonazepam vs placebo in panic disorder treatment. Arquivos de Neuro-Psiquiatria 58(4):1025–1029, 2000PubMed

94.

Seedat S, Stein MB: Double-blind, placebo-controlled assessment of combined clonazepam with paroxetine compared with paroxetine monotherapy for generalized social anxiety disorder. Journal of Clinical Psychiatry 65(2):244–248, 2004PubMed

95.

Clark RE, Xie H, Brunette MF: Benzodiazepine prescription practices and substance abuse in persons with severe mental illness. Journal of Clinical Psychiatry 65:151–155, 2004PubMedCrossRef

96.

Brunette MF, Noordsy DL, Xie H, et al.: Benzodiazepine use and abuse among patients with severe mental illness and co-occurring substance use disorders. Psychiatric Services 54:1395–1401, 2003PubMedCrossRef

97.

Weiss RD, Greenfield SF, Najavits LM, et al.: Medication compliance among patients with bipolar disorder and substance use disorder. Journal of Clinical Psychiatry 59:172–174, 1998PubMed

98.

Turkington D, Gill P: Mania induced by lorazepam withdrawal: a report of two cases. Journal of Affective Disorders 17(1):93–95, 1989PubMedCrossRef

99.

Miller NS, Guttman JC: The integration of pharmacological therapy for comorbid psychiatric and addictive disorders. Journal of Psychoactive Drugs 29:249–254, 1997PubMed

100.

Wilhelm FH, Roth WT: Acute and delayed effects of alprazolam on flight phobics during exposure. Behavior Research and Therapy 35:831–841, 1997CrossRef

101.

Gelpin E, Bonne O, Peri T, et al.: Treatment of recent trauma survivors with benzodiazepines: a prospective study. Journal of Clinical Psychiatry 57:390–394, 1996PubMed

102.

Chouinard G, Labonte A, Fontaine R, et al.: New concepts in benzodiazepine therapy: rebound anxiety and new indications for the more potent benzodiazepines. Progress in Neuropsychopharmacology and Biological Psychiatry 7:669–673, 1983CrossRef

103.

Dusseldorp E, Spinhoven P, Bakker A, et al.: Which panic disorder patients benefit from which treatment: cognitive therapy or antidepressants? Psychotherapy and Psychosomatics 76(3):154–61, 2007PubMedCrossRef

104.

Anderson RA, Rees CS: Group versus individual cognitive-behavioral treatment for obsessive-compulsive disorder: a controlled trial. Behavior Research and Therapy 45(1):123–37, 2007CrossRef

105.

Linden M, Zubraegel D, Baer T, et al.: Efficacy of cognitive behaviour therapy in generalized anxiety disorders. Results of a controlled clinical trial (Berlin CBT-GAD Study). Psychotherapy and Psychosomatics 74:36–42, 2005PubMedCrossRef

106.

Blanchard EB, Hickling EJ, Devineni T, et al.: A controlled evaluation of cognitive behavioural therapy for posttraumatic stress in motor vehicle accident survivors. Behavior Research and Therapy 41(1):79–96, 2003CrossRef

107.

Mitte K: A meta-analysis of psycho- and pharmacotherapy in panic disorder with and without agoraphobia. Journal of Affective Disorders 88:27–45, 2005PubMedCrossRef

108.

Hollon SD, Stewart MO, Strunk D: Enduring effects for cognitive behavior therapy in the treatment of depression and anxiety. Annual Review of Psychology 57:285–315, 2006PubMedCrossRef

109.

Fava GA, Ruini C, Rafanelli C: Sequential treatment of mood and anxiety disorders. Journal of Clinical Psychiatry 66:1392–1400, 2005PubMed

110.

Scott J, Paykel E, Morriss R, et al.: Cognitive behavioral therapy for severe and recurrent bipolar disorders: a randomized controlled trial. British Journal of Psychiatry 188:313–320, 2006PubMedCrossRef

111.

Bell JR, Mitchell PB, Corry JC, et al.: A randomized controlled trial of cognition therapy for bipolar disorder: focus on long-term change. Journal of Clinical Psychiatry 67:277–286, 2006CrossRef

Titel: Comorbid Anxiety in Bipolar Disorder Alters Treatment and Prognosis
verfasst von: Rif S. El-Mallakh
Michael Hollifield
Publikationsdatum: 01.06.2008
Verlag: Springer US
Erschienen in: Psychiatric Quarterly / Ausgabe 2/2008
Print ISSN: 0033-2720
Elektronische ISSN: 1573-6709
DOI: https://doi.org/10.1007/s11126-008-9071-5

Neu im Fachgebiet Psychiatrie

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

23.04.2024 Depression antepartal oder postpartal Nachrichten

Bislang gibt es kein Medikament zur Prävention von Wochenbettdepressionen. Das Injektionsanästhetikum Esketamin könnte womöglich diese Lücke füllen.

„Psychotherapie ist auch bei sehr alten Menschen hochwirksam!“

22.04.2024 DGIM 2024 Kongressbericht

Die Kombination aus Medikamenten und Psychotherapie gilt als effektivster Ansatz bei Depressionen. Das ist bei betagten Menschen nicht anders, trotz Besonderheiten.

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

22.04.2024 DGIM 2024 Nachrichten

Um Menschen nach der Flucht aus einem Krisengebiet bestmöglich medizinisch betreuen zu können, ist es gut zu wissen, welche Erkrankungen im jeweiligen Herkunftsland häufig sind. Dabei hilft eine Internetseite der CDC (Centers for Disease Control and Prevention).

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2008

Comparison of Clozapine Response for Inpatients in the Research Setting Versus Routine Clinical Practice

Both Atomoxetine and Stimulants Improve Quality of Life in an ADHD Population Treated in a Community Clinic

Reducing Inpatient Aggression: Does Paying Attention Pay Off?

The Use of Data to Assist in the Design of a New Service System for Homeless Veterans in New York City